Abstract

IntroductionAntiphospholipid syndrome (APS) is characterized by recurrent arterial and venous thrombosis and detection of antiphospholipid antibodies (aPLs). This syndrome may be associated with connective tissue disorders, or with malignancies, but it may also appear in isolated form (primary APS). We report on a pediatric patient presenting with acute adrenal failure as the first manifestation of primary APS.Case reportA previously healthy 11-year-old boy developed fever, abdominal pain, and vomiting. An abdominal computed tomography scan showed nodular lesions in the adrenal glands. He was referred to our Department and a diagnosis of APS and acute adrenal failure was considered, based on positive aPLs (IgG and IgM), elevated ACTH levels and low cortisol levels. Other features were anemia, thrombocytopenia, elevated inflammatory parameters, hypergammaglobulinemia, prolonged partial thromboplastin time, positive antinuclear, anticardiolipin, anti-platelet antibodies, with negative double-stranded DNA antibodies. Lupus anticoagulant and Coomb’s tests were positive. MRI revealed a bilateral adrenal hemorrhage. A treatment with intravenous metylprednisolone, followed by oral prednisone and anticoagulant, was started, resulting in a progressive improvement. After 2 months he also showed hyponatremia and elevated renine levels, indicating a mineralcocorticoid deficiency, requiring fludrocortisones therapy.ConclusionThe development of acute adrenal failure from bilateral adrenal haemorrhage in the context of APS is a rare but life-threatening event that should be promptly recognized and treated. Moreover, this case emphasizes the importance of the assessment of aPLs in patients with acute adrenal failure in the context of an autoreaction.

Highlights

  • Antiphospholipid syndrome (APS) is characterized by recurrent arterial and venous thrombosis and detection of antiphospholipid antibodies

  • The development of acute adrenal failure from bilateral adrenal haemorrhage in the context of APS is a rare but life-threatening event that should be promptly recognized and treated. This case emphasizes the importance of the assessment of Antiphospholipid antibodies (aPLs) in patients with acute adrenal failure in the context of an autoreaction

  • APS is an autoimmune disorder characterized by the persistent detection of antiphospholipid antibodies and various clinical manifestations, the most common being venous and arterial thrombotic events, recurrent fetal loss, thrombocytopenia, livedo reticularis and neurological manifestations

Read more

Summary

Conclusion

The development of acute adrenal failure due to bilateral adrenal haemorrhage in the context of antiphospholipid syndrome is a rare but life-threatening event that should be promptly recognized and treated. Our case emphasizes the importance in the assessment of antiphospholipid antibodies in all patients with rapidly progressive acute adrenal failure in particular when other autoimmune signs and symptoms are present. Consent Written informed consent was obtained from the parents of the patient for publication of this Case report and any accompanying images. Competing interests The author(s) declare that they have no competing interests. Authors’ contribution All authors have participated in drafting of the manuscript and/or critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.

Background
Discussion
Findings
22. Mackworth-Young CG
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.